Tumors With Aberrations in ALK or ROS1
1 clinical trials · Condition
◉ Watch Tumors With Aberrations in ALK or ROS1
| Record | Firm | Date |
|---|---|---|
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (NCT02186821) | Novartis Pharmaceuticals | 2014-09-17 |
Track Tumors With Aberrations in ALK or ROS1 automatically
Every clearance here is in the API, with alerts when new ones post.